We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals
FENC

30 hedge funds and large institutions have $36M invested in Fennec Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.27% less ownership

Funds ownership: 48.44% → 45.17% (-3.3%)

23% less capital invested

Capital invested by funds: $46.7M → $36M (-$10.8M)

39% less funds holding

Funds holding: 49 → 30 (-19)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

85% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 20

Holders
30
Holders Change
-19
Holders Change %
-38.78%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
13
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SCM
Solas Capital Management
Connecticut
+$3.6M
2
USAA
United Services Automobile Association
Texas
+$237K
3
PP
Paloma Partners
Connecticut
+$230K
4
Millennium Management
Millennium Management
New York
+$202K
5
GIM
Granahan Investment Management
Massachusetts
+$119K

Top Sellers

1
BlackRock
BlackRock
New York
-$2.13M
2
OM
Opaleye Management
Massachusetts
-$1.42M
3
PI
Putnam Investments
Massachusetts
-$1.27M
4
State Street
State Street
Massachusetts
-$812K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$223K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCA
1
Southpoint Capital Advisors
New York
$16M – – –
ACA
2
Avoro Capital Advisors
New York
$4.42M – – –
6CM
3
683 Capital Management
New York
$3.88M – – –
SCM
4
Solas Capital Management
Connecticut
$3.4M +$3.6M +849,979 New
EAM
5
Eventide Asset Management
Massachusetts
$2.88M – – –
GIM
6
Granahan Investment Management
Massachusetts
$1.76M +$119K +28,151 +7%
OM
7
Opaleye Management
Massachusetts
$1.18M -$1.42M -335,000 -53%
USAA
8
United Services Automobile Association
Texas
$920K +$237K +55,933 +32%
Northern Trust
9
Northern Trust
Illinois
$388K -$21.6K -5,105 -5%
OAM
10
Oxford Asset Management
United Kingdom
$301K -$40.3K -9,514 -11%
PP
11
Paloma Partners
Connecticut
$218K +$230K +54,400 New
Millennium Management
12
Millennium Management
New York
$191K +$202K +47,634 New
BlackRock
13
BlackRock
New York
$145K -$2.13M -503,491 -93%
WMSA
14
Weiss Multi-Strategy Advisers
New York
$100K – – –
HFM
15
Hartford Financial Management
Connecticut
$81K +$33.9K +8,000 +65%
Bank of America
16
Bank of America
North Carolina
$36K +$28.2K +6,663 +274%
MAM
17
Meeder Asset Management
Ohio
$19K -$19.5K -4,595 -49%
Deutsche Bank
18
Deutsche Bank
Germany
$11K -$183K -43,331 -94%
Citigroup
19
Citigroup
New York
$8K -$6.52K -1,540 -46%
Legal & General Group
20
Legal & General Group
United Kingdom
$7K – – –
BNP Paribas Financial Markets
21
BNP Paribas Financial Markets
France
$5.66K -$5.27K -1,244 -47%
Wells Fargo
22
Wells Fargo
California
$4K -$60.7K -14,334 -93%
Barclays
23
Barclays
United Kingdom
$2K -$12.2K -2,873 -84%
Morgan Stanley
24
Morgan Stanley
New York
$1K -$14.4K -3,393 -96%
PCM
25
Prelude Capital Management
New York
$1K -$55 -13 -4%
1
2

FENC Hedge Fund Activity: Q2 2019 in Review

30 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2019, worth a combined $36M — down 23% from $46.7M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of FENC and 3 opened new positions — a net loss of 17 holders — while 13 trimmed existing stakes and 7 added.

The largest buyer was Solas Capital Management, opening a new position worth an estimated $3.6M. The largest seller was BlackRock, cutting an estimated $2.13M.

  • 30 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2019, down from 49 in Q1 2019.
  • Funds reported $36M of Fennec Pharmaceuticals stock for Q2 2019, down 23% quarter-over-quarter.
  • 3 funds opened new Fennec Pharmaceuticals positions in Q2 2019 and 20 closed out, a net change of -17 holders.
  • The largest Fennec Pharmaceuticals buyer in Q2 2019 was Solas Capital Management, an estimated $3.6M added.
  • The largest Fennec Pharmaceuticals seller in Q2 2019 was BlackRock, an estimated $2.13M sold.

Based on aggregated 13F filings for Q2 2019.